
SARCOMA
Latest News
Latest Videos

CME Content
More News

Enrolling pediatric patients and identifying biomarkers for response are the priorities for research of ozekibart in Ewing sarcoma.

Rashmi Chugh, MD, discusses the early outcomes of a trial of ozekibart plus chemotherapy in Ewing sarcoma.

ODD status was granted based on tumor response rates with eftilagimod alfa and pembrolizumab of more than 3-fold above historical benchmarks from radiotherapy alone.

In patients with high-grade uterine sarcoma who achieved disease control, cabozantinib did not prolong survival and had added toxicity.

Ozekibart, irinotecan, and temozolomide yielded a high response rate and maintained tolerability in patients with relapsed/refractory Ewing sarcoma.

Ipsen pulls Tazverik worldwide after SYMPHONY-1 flags secondary blood cancer risk, halting trials and access programs and moving patients to standard care.

Erica Pimenta, MD, PhD, discussed the goals and key findings from her and her colleagues’ research into IGF-1 and GLP-1 signaling pathways in liposarcoma.

Tumor-infiltrating lymphocyte therapy yielded favorable results in a small cohort of patients with soft tissue sarcoma, leading to plans for a larger trial.

Cabozantinib plus temozolomide led to favorable short-term progression-free survival in a single-arm trial of patients with advanced leiomyosarcoma.


The FDA gave breakthrough therapy designation to bezuclastinib plus sunitinib in imatinib-refractory gastrointestinal stromal tumors.

The FDA granted Orphan Drug Designation to LP-284, a small molecule targeting DNA damage repair mechanisms, for soft tissue sarcoma.

FDA fast tracks ADCE-D01, a promising treatment for soft tissue sarcoma, aiming to expedite patient access and improve survival rates.

During a live event, Steven I. Robinson, MBBS, discussed guideline-concordant active surveillance and systemic therapies for managing desmoid tumors.

FDA grants fast track designation to CLD-201, an innovative therapy for soft tissue sarcoma, enhancing its development and review process.

ASCO 2025 showcased breakthroughs in sarcoma treatment, emphasizing precision medicine, immunotherapy, and promising new therapies for rare cancers.

A phase 2a trial shows tigilanol tiglate achieves an 80% response rate in soft tissue sarcoma, offering hope for effective treatment options.

During a live event, Hari Deshpande, MD, and participants discussed the DeFi trial and the management of nirogacestat in progressive desmoid tumors.


































